Skip to main content
VALIRX PLC logo

VALIRX PLC — Investor Relations & Filings

Ticker · VAL ISIN · GB00BLH13C52 LEI · 213800VQKB9SJCQDET40 IL Professional, scientific and technical activities
Open in API
Filings indexed 574 across all filing types
Latest filing 2016-02-17 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL VAL

About VALIRX PLC

https://www.valirx.com/

ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.

Recent filings

Filing Released Lang Actions
Placing to raise £0.5 million
Share Issue/Capital Change Classification · 1% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content explicitly announces a 'Placing to raise £0.5 million' through the issuance of new ordinary shares. This action—raising capital through an equity placement—falls directly under the definition of 'Capital/Financing Update' (CAP). Although it is distributed via RNS, the core subject matter is financing, making CAP the most specific classification. Since this is the full announcement text and not just a notice that a report is attached, it is not RPA or RNS.
2016-02-17 English
VAL201 Clinical Trial Update
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated February 16, 2016. The content is a brief update titled 'VAL201 CLINICAL TRIAL UPDATE' regarding a Cohort Review Committee approval for dose escalation. This is a short, specific announcement concerning company operations (clinical trial progress) released via the RNS system (London Stock Exchange's news service). Since it is a brief operational update disseminated through the regulatory news service and does not fit neatly into specific financial reports (like 10-K, IR, ER) or specific corporate actions (like DIV, CAP), it falls best under the general regulatory announcement category, RNS.
2016-02-16 English
Quarterly Update on Clinical Progress
Regulatory Filings Classification · 1% confidence The document is identified by the presence of an 'RNS Number' and the header 'RNS Number : 4426O'. The content provides a 'QUARTERLY UPDATE ON CLINICAL PROGRESS' detailing the status of clinical trials (VAL201 and VAL401) for a life science company. This is a specific operational update, not a comprehensive annual report (10-K), a formal earnings release (ER), or a general regulatory filing (RNS) that lacks a better fit. Since it provides detailed operational and clinical progress updates, it aligns best with an Investor Presentation (IP) or a detailed management report, but given the context of clinical trial updates often being disseminated via RNS, and the document structure being a formal announcement rather than a slide deck, it is a specific type of regulatory disclosure. However, none of the provided codes perfectly capture a 'Clinical Progress Update'. It is not a standard Earnings Release (ER) which focuses on financial results. It is more detailed than a simple announcement of a report (RPA). Since it details ongoing business activities and progress, it is closest to an Investor Presentation (IP) in terms of content depth, or potentially a specialized Regulatory Filing (RNS) if no other category fits. Given the detailed nature of the clinical trial progress, it functions as an update for investors about the core business pipeline, making 'Investor Presentation' (IP) a plausible fit for the content type, even if the distribution channel is RNS. However, looking closely at the definitions, 'RNS' is the fallback for miscellaneous filings. Since this is a specific update disseminated via RNS, and it doesn't fit ER, IR, 10-K, or MDA (which usually covers financial performance explanation), the most accurate classification based on the provided list for a non-standard, detailed operational update distributed via the RNS system is the general 'Regulatory Filings' (RNS) category, as it is a specific regulatory announcement that doesn't map to the other specific operational/financial reports.
2016-02-09 English
Clinical Phase Development Update
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's news service (RNS). The content provides an update on clinical trial progress for two compounds (VAL201 and VAL401), which falls under general operational or scientific updates. Since it is a formal, brief announcement disseminated through the RNS system and does not fit neatly into specific categories like Earnings Release (ER), Interim Report (IR), or Director's Dealing (DIRS), the most appropriate classification is the general regulatory announcement category, RNS. The document length (4735 chars) is not extremely short, but the primary identifier is the RNS header and format.
2015-11-19 English
ValiRx establishes US office in Boston, MA
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated 05 November 2015. The content announces a strategic business development: establishing a US office and strengthening the advisory team. This type of announcement, which conveys material, non-financial operational news to the market via an official channel (indicated by the RNS header), fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (like 10-K, ER, IR), a management change (MANG), or a director's dealing (DIRS). Since it is a general regulatory announcement disseminated through the London Stock Exchange's news service (RNS), the most appropriate code is RNS.
2015-11-05 English
Collaboration Agreement
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement. The content details a 'Collaboration Agreement' between ValiRx Plc and Pharmatest Services Ltd regarding the development of GeneICE technology. This type of announcement, detailing a significant business development (a partnership/agreement) released via the London Stock Exchange's news service (RNS), fits best under the general 'Regulatory Filings' category, as it is not a formal financial report (10-K, IR, ER), a management change (MANG), or a specific transaction like a share buyback (POS) or dividend (DIV). It is a general corporate update disseminated through the regulatory channel.
2015-10-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.